J. Safra Sarasin Holding AG Sells 9,116 Shares of Elevance Health, Inc. $ELV

J. Safra Sarasin Holding AG lowered its position in shares of Elevance Health, Inc. (NYSE:ELV) by 63.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,285 shares of the company’s stock after selling 9,116 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Elevance Health were worth $1,853,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ELV. Murphy Middleton Hinkle & Parker Inc. bought a new position in Elevance Health during the 4th quarter valued at approximately $5,941,000. Evergreen Wealth Management LLC grew its position in shares of Elevance Health by 33.5% in the 3rd quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after buying an additional 4,336 shares during the last quarter. Blume Capital Management Inc. grew its position in shares of Elevance Health by 236.7% in the 3rd quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock worth $1,986,000 after buying an additional 4,320 shares during the last quarter. Canoe Financial LP increased its stake in shares of Elevance Health by 18.1% during the third quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock valued at $125,823,000 after buying an additional 59,743 shares during the period. Finally, Synergy Asset Management LLC increased its stake in shares of Elevance Health by 100.0% during the third quarter. Synergy Asset Management LLC now owns 104,334 shares of the company’s stock valued at $33,712,000 after buying an additional 52,167 shares during the period. Institutional investors own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ELV shares. JPMorgan Chase & Co. raised their price target on Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Barclays reduced their price objective on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a research report on Friday, January 30th. Wells Fargo & Company decreased their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Leerink Partners raised their target price on shares of Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Finally, Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price on the stock. in a research note on Tuesday, February 3rd. Twelve equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $387.40.

Elevance Health Price Performance

Shares of ELV stock opened at $293.10 on Wednesday. The business’s fifty day moving average is $318.92 and its 200 day moving average is $332.55. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The stock has a market cap of $64.38 billion, a price-to-earnings ratio of 11.67, a PEG ratio of 1.56 and a beta of 0.51. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same quarter last year, the firm posted $3.84 earnings per share. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were given a dividend of $1.72 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.3%. Elevance Health’s dividend payout ratio is 27.39%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.